FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1807350208> ?p ?o ?g. }

• W1807350208 abstract "Basic research of gefitinib (Iressa, ZD1839) has demonstrated the combination effects of gefitinib and chemotherapy were sequence-dependent. To evaluate the efficacy of sequential administration of gefitinib following a minor response or partial response to two to three cycles of chemotherapy, a phase II clinical trial was done in Chinese patients with advanced non-small-cell lung cancer (NSCLC).Thirty-three consecutive patients with advanced NSCLC that had been pretreated with at least one chemotherapeutic regimen and were responding to chemotherapy following 2 to 3 cycles of treatment, entered the trial from May 2004 to February 2006. Patients received gefitinib at an oral dose of 250 mg once daily for 4 weeks.Thirty-three patients were evaluable for response and toxicity. The objective response rate was 24.2% (8 of 33) (95% CI, 11% to 42%). The symptom improvement rate was 54.5% (18 of 33) (95% CI, 41% to 69%). The median duration of response was 7 months (95%CI, 4.0 to 13.2 months). The median time to disease progression (TTP) was 6.5 months (95%CI, 0.7 to 16.6 months). The median overall survival time (OS) was 9.8 months (range, 2.1 to 18.0 months), and the actuarial 1-year survival was 36.4%. Toxicity was relatively mild and included only one patient (3.0%) with grade 4 diarrhea, 1 (3.0%) with grade 3 rash, 1 (3.0%) with grade 3 nausea, and 1 with grade 3 vomiting (3.0%).Preliminary results suggest that sequential administration of gefitinib following a response to chemotherapy may be beneficial for Chinese patients with advanced NSCLC. Further randomized clinical trials are needed." @default.
• W1807350208 created "2016-06-24" @default.
• W1807350208 creator A5003642180 @default.
• W1807350208 creator A5020037074 @default.
• W1807350208 creator A5029116476 @default.
• W1807350208 creator A5033623540 @default.
• W1807350208 creator A5065378680 @default.
• W1807350208 creator A5085211609 @default.
• W1807350208 date "2006-12-01" @default.
• W1807350208 modified "2023-10-17" @default.
• W1807350208 title "Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer" @default.
• W1807350208 cites W1748441280 @default.
• W1807350208 cites W1853219928 @default.
• W1807350208 cites W1964431856 @default.
• W1807350208 cites W1966035137 @default.
• W1807350208 cites W1969918779 @default.
• W1807350208 cites W1970048391 @default.
• W1807350208 cites W1970346999 @default.
• W1807350208 cites W1995634658 @default.
• W1807350208 cites W2006994284 @default.
• W1807350208 cites W2013889785 @default.
• W1807350208 cites W2060729249 @default.
• W1807350208 cites W2074190059 @default.
• W1807350208 cites W2078607283 @default.
• W1807350208 cites W2082118762 @default.
• W1807350208 cites W2110835998 @default.
• W1807350208 cites W2111710483 @default.
• W1807350208 cites W2119321434 @default.
• W1807350208 cites W2120742888 @default.
• W1807350208 cites W2127101185 @default.
• W1807350208 cites W2128048179 @default.
• W1807350208 cites W2144315144 @default.
• W1807350208 cites W2146404049 @default.
• W1807350208 cites W2155236705 @default.
• W1807350208 cites W2161731922 @default.
• W1807350208 cites W2170549240 @default.
• W1807350208 cites W2226300232 @default.
• W1807350208 cites W2474438615 @default.
• W1807350208 cites W4293241248 @default.
• W1807350208 cites W1966032368 @default.
• W1807350208 doi "https://doi.org/10.1186/1471-2407-6-288" @default.
• W1807350208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1764758" @default.
• W1807350208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17173694" @default.
• W1807350208 hasPublicationYear "2006" @default.
• W1807350208 type Work @default.
• W1807350208 sameAs 1807350208 @default.
• W1807350208 citedByCount "5" @default.
• W1807350208 countsByYear W18073502082012 @default.
• W1807350208 countsByYear W18073502082013 @default.
• W1807350208 countsByYear W18073502082015 @default.
• W1807350208 crossrefType "journal-article" @default.
• W1807350208 hasAuthorship W1807350208A5003642180 @default.
• W1807350208 hasAuthorship W1807350208A5020037074 @default.
• W1807350208 hasAuthorship W1807350208A5029116476 @default.
• W1807350208 hasAuthorship W1807350208A5033623540 @default.
• W1807350208 hasAuthorship W1807350208A5065378680 @default.
• W1807350208 hasAuthorship W1807350208A5085211609 @default.
• W1807350208 hasBestOaLocation W18073502081 @default.
• W1807350208 hasConcept C121608353 @default.
• W1807350208 hasConcept C126322002 @default.
• W1807350208 hasConcept C141071460 @default.
• W1807350208 hasConcept C143998085 @default.
• W1807350208 hasConcept C2776256026 @default.
• W1807350208 hasConcept C2776694085 @default.
• W1807350208 hasConcept C2778496288 @default.
• W1807350208 hasConcept C2778570526 @default.
• W1807350208 hasConcept C2778822529 @default.
• W1807350208 hasConcept C2779438470 @default.
• W1807350208 hasConcept C2780580376 @default.
• W1807350208 hasConcept C2780580887 @default.
• W1807350208 hasConcept C2781413609 @default.
• W1807350208 hasConcept C71924100 @default.
• W1807350208 hasConcept C90924648 @default.
• W1807350208 hasConceptScore W1807350208C121608353 @default.
• W1807350208 hasConceptScore W1807350208C126322002 @default.
• W1807350208 hasConceptScore W1807350208C141071460 @default.
• W1807350208 hasConceptScore W1807350208C143998085 @default.
• W1807350208 hasConceptScore W1807350208C2776256026 @default.
• W1807350208 hasConceptScore W1807350208C2776694085 @default.
• W1807350208 hasConceptScore W1807350208C2778496288 @default.
• W1807350208 hasConceptScore W1807350208C2778570526 @default.
• W1807350208 hasConceptScore W1807350208C2778822529 @default.
• W1807350208 hasConceptScore W1807350208C2779438470 @default.
• W1807350208 hasConceptScore W1807350208C2780580376 @default.
• W1807350208 hasConceptScore W1807350208C2780580887 @default.
• W1807350208 hasConceptScore W1807350208C2781413609 @default.
• W1807350208 hasConceptScore W1807350208C71924100 @default.
• W1807350208 hasConceptScore W1807350208C90924648 @default.
• W1807350208 hasIssue "1" @default.
• W1807350208 hasLocation W18073502081 @default.
• W1807350208 hasLocation W18073502082 @default.
• W1807350208 hasLocation W18073502083 @default.
• W1807350208 hasLocation W18073502084 @default.
• W1807350208 hasOpenAccess W1807350208 @default.
• W1807350208 hasPrimaryLocation W18073502081 @default.
• W1807350208 hasRelatedWork W1971941190 @default.
• W1807350208 hasRelatedWork W2243375749 @default.
• W1807350208 hasRelatedWork W2358450743 @default.
• W1807350208 hasRelatedWork W2372621195 @default.
• W1807350208 hasRelatedWork W2373559812 @default.

• next